Dr Reddy's launches generic attention deficit disorder drug in US market
New Delhi, Sep 3 () Dr Reddy's Laboratories on Thursday said it has launched Methylphenidate Hydrochloride extended-release tablets, used to treat attention deficit disorder (ADD), in the US market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 3, 2020 Category: Pharmaceuticals Source Type: news

Methylphenidate and the risk of burn injury among children with attention-deficit/hyperactivity disorder - Chen VCH, Yang YH, Yu Kuo T, Lu ML, Tseng WT, Hou TY, Yeh JY, Lee CTC, Chen YL, Lee MJ, Dewey ME, Gossop M.
AIMS: Attention-deficit/hyperactivity disorder (ADHD) is associated with a higher risk of burn injury than in the normal population. Nevertheless, the influence of methylphenidate (MPH) on the risk of burn injury remains unclear. This retrospective cohort ... (Source: SafetyLit)
Source: SafetyLit - July 23, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study - Chen VCH, Chan HL, Wu SI, Lu ML, Dewey ME, Stewart R, Lee CTC.
BACKGROUND: Little is known about methylphenidate (MPH) use and mortality outcomes. AIMS: To investigate the association between MPH use and mortality among children with an attention-deficit hyperactivity disorder (ADHD) diagnosis. METHOD: This po... (Source: SafetyLit)
Source: SafetyLit - July 17, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Dopamine promotes cognitive effort by biasing the benefits versus costs of cognitive work
Stimulants such as methylphenidate are increasingly used for cognitive enhancement but precise mechanisms are unknown. We found that methylphenidate boosts willingness to expend cognitive effort by altering the benefit-to-cost ratio of cognitive work. Willingness to expend effort was greater for participants with higher striatal dopamine synthesis capacity, whereas methylphenidate and sulpiride, a selective D2 receptor antagonist, increased cognitive motivation more for participants with lower synthesis capacity. A sequential sampling model informed by momentary gaze revealed that decisions to expend effort are related to ...
Source: ScienceNOW - March 19, 2020 Category: Science Authors: Westbrook, A., van den Bosch, R., Määttä, J. I., Hofmans, L., Papadopetraki, D., Cools, R., Frank, M. J. Tags: Neuroscience, Psychology reports Source Type: news

Association of methylphenidate use and traditional/cyberbullying - Tural Hesapcioglu S, Kandemir G.
This study aims to determine whether there is a difference in terms of traditional/cyberbullying or victimization among adolescents receiving methylphenidate for attention deficit hyperactivity disorder (ADHD) and treatment-na ïve adolescents w... (Source: SafetyLit)
Source: SafetyLit - February 8, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

The effects of methylphenidate on stress fractures in patients age 10-29: a national database study - DeFroda SF, Quinn M, Yang DS, Daniels AH, Owens BD.
This study further investigates this effect utilizing a large na... (Source: SafetyLit)
Source: SafetyLit - February 7, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Rich rewards: Scientists reveal ADHD medication's effect on the brain
(Okinawa Institute of Science and Technology (OIST) Graduate University) Researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) have identified how certain areas of the human brain respond to methylphenidate -- a stimulant drug which is used to treat symptoms of ADHD. The work may help researchers understand the precise mechanism of the drug and ultimately develop more targeted medicines for the condition. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 17, 2020 Category: Biology Source Type: news

Medicines Supply Communications
Delmosart (methylphenidate) 18mg prolonged-release tablets The Department of Health and Social Care (DHSC) has issued a Medicine Supply Notification for Delmosart (methylphenidate) 18mg prolonged-rel (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news

' Medium' Dose of Common ADHD Drug Most Effective for Kids'Medium' Dose of Common ADHD Drug Most Effective for Kids
Clinicians are being warned against overtreating children with methylphenidate, and to focus on neurocognitive function over behavior, based on results of a new meta-analysis.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - September 12, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

MRI shows effect of Ritalin on kids' brains
MR images indicate that methylphenidate, also known as Ritalin, can affect...Read more on AuntMinnie.comRelated Reading: fMRI shows how game therapy 'rewires' ADHD brains MRI shows smaller brain volume in kids with ADHD MR spectroscopy links ADHD drugs to positive emotions MRI, radiomics help diagnose, discern ADHD subtypes MRI links brain volume to ADHD (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 16, 2019 Category: Radiology Source Type: news

ADHD Drug Changes Kids' Brains, Maybe for the Better ADHD Drug Changes Kids' Brains, Maybe for the Better
A new study suggests that methylphenidate changes the brains of kids with attention-deficit/hyperactivity disorder. Could this be a good thing?Medscape (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - August 14, 2019 Category: Pediatrics Tags: Radiology Commentary Source Type: news

Common ADHD Medication May Affect Brain Development Common ADHD Medication May Affect Brain Development
Treatment with methylphenidate appears to affect the development of the brain's signal-carrying white matter in boys with ADHD, new research suggests.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - August 13, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Commonly prescribed ADHD drug Ritalin 'affects brain development in children'
Ritalin, the brand name for methylphenidate, focuses the brain. A Dutch study using MRI scans showed children had less white matter in the brain while taking the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - August 13, 2019 Category: Consumer Health News Source Type: news

ADHD Medication Methylphenidate May Alter Boys' Brains
TUESDAY, Aug. 13, 2019 -- One of the most popular and effective medications used to treat attention-deficit/hyperactivity disorder (ADHD) appears to alter the brains of boys with the disorder, a new study shows. While the researchers couldn't say... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 13, 2019 Category: General Medicine Source Type: news

Methylphenidate Treatment Tied to Brain Changes in Boys With ADHD
TUESDAY, Aug. 13, 2019 -- Treatment with methylphenidate (MPH) affects specific tracts in brain white matter in boys with attention-deficit/hyperactivity disorder (ADHD), according to a study published online Aug. 13 in Radiology. Cheima Bouziane,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Everything you need to know about methylphenidate
Methylphenidate is a stimulant drug that doctors prescribe to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. Learn about how it works, its side effects, and typical dosages here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 12, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Medical News Today: What is the difference between Concerta and Ritalin?
Concerta and Ritalin are both prescription drugs containing the active ingredient methylphenidate hydrochloride. Learn about the differences between them here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 4, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study - Hollis C, Chen Q, Chang Z, Quinn PD, Viktorin A, Lichtenstein P, D'Onofrio B, Land én M, Larsson H.
BACKGROUND: There is a clinical concern that prescribing methylphenidate, the most common pharmacological treatment for attention-deficit hyperactivity disorder (ADHD), might increase the risk of psychotic events, particularly in young people with a histor... (Source: SafetyLit)
Source: SafetyLit - June 26, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 3, 2019 Category: Drugs & Pharmacology Source Type: news

Medical News Today: What are the side effects and risks of Ritalin?
Ritalin (methylphenidate) is a stimulant medication for the treatment of ADHD and narcolepsy. Ritalin can cause side effects and has the potential for misuse and addiction. Researchers are investigating the long-term safety and effectiveness of this drug in children and adolescents. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 31, 2019 Category: Consumer Health News Tags: ADHD / ADD Source Type: news

The association between attention-deficit hyperactivity disorder, injuries, and methylphenidate - Shem-Tov S, Chodick G, Weitzman D, Koren G.
Objective. To evaluate the relationship between attention-deficit hyperactivity disorder (ADHD) and injuries and to verify whether methylphenidate (MPH), is associated with decreasing the risk of injuries. Methods. A retrospective cohort ... (Source: SafetyLit)
Source: SafetyLit - May 26, 2019 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Methylphenidate Capsules for Morning ADHD Symptom Control Methylphenidate Capsules for Morning ADHD Symptom Control
Newly approved delayed- and extended-release methylphenidate capsules designed for bedtime administration may provide better early morning symptom control for ADHD patients.Pediatric Pharmacotherapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2019 Category: Consumer Health News Tags: Pediatrics Journal Article Source Type: news

Amid America's opioid crisis, deaths from stimulants are steadily rising
Overdose deaths involving cocaine and psychotstimulants such as methamphematines, MDMA, methylphenidate (commonly sold as Ritalin) and caffeine have been steadily rising, according to a new report from the US Centers for Disease Control and Prevention. (Source: CNN.com - Health)
Source: CNN.com - Health - May 2, 2019 Category: Consumer Health News Source Type: news

Lannett To Launch Generic Concerta(R), AB-rated Methylphenidate Hydrochloride ER Tablets
PHILADELPHIA, April 30, 2019 -- (Healthcare Sales & Marketing Network) -- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg,... Biopharmaceuticals, Generics, Product Launch Lannett, Concerta , Methylphenidate (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Medical Device To Treat ADHD In Children
(CNN) — The first medical device to treat childhood attention deficit hyperactivity disorder, or ADHD, was OK’d Friday by the US Food and Drug Administration. Designated for children ages 7 to 12 who are not currently on medication for the disorder, the device delivers a low-level electrical pulse to the parts of the brain responsible for ADHD symptoms. “This new device offers a safe, non-drug option for treatment of ADHD in pediatric patients through the use of mild nerve stimulation, a first of its kind,” Carlos Peña, director of the Division of Neurological and Physical Medicine Devices in...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 22, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN ADHD Source Type: news

Can delayed/extended-release methylphenidate allow for once daily evening dosing in ADHD?
(Mary Ann Liebert, Inc./Genetic Engineering News) A new three-part study showed that a delayed-release, extended-release form of methylphenidate could be given to adults in the evening with or without food and would not exert any clinically meaningful effect for at least 10 hours after administration. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 2, 2019 Category: International Medicine & Public Health Source Type: news

ANI Pharmaceuticals Announces Two Generic Product Launches
BAUDETTE, Minn., March 27, 2019 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release T... Biopharmaceuticals, Generics, Product Launch ANI Pharmaceuticals, Methylphenidate, Attention Deficit Hyperactivity Disorder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2019 Category: Pharmaceuticals Source Type: news

Childhood methylphenidate treatment predicts antidepressant use during adolescence
(Bar-Ilan University) A new, 12-year longitudinal study, which monitored 6,830 children from early childhood into adolescence, has shown that consistent treatment with MPH-based medications during childhood increases the risk of antidepressant use during adolescence. The study is the first of its kind to examine the connection between children diagnosed with ADHD and prescribed MPH between the ages of six and eight, and future dispensed prescriptions of antidepressants. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 27, 2019 Category: International Medicine & Public Health Source Type: news

In Youth With ADHD, New-Onset Psychosis Up With Amphetamines
THURSDAY, March 21, 2019 -- For adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD), new-onset psychosis occurs more often with amphetamine use versus methylphenidate use, according to a study published in the March 21... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2019 Category: Pharmaceuticals Source Type: news

Some ADHD Meds Tied to a Higher Psychosis Risk Than Others Some ADHD Meds Tied to a Higher Psychosis Risk Than Others
Amphetamines are associated with a higher psychosis risk than methylphenidate in young patients who take these agents to treat attention deficit hyperactivity disorder.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - March 20, 2019 Category: Primary Care Tags: Psychiatry News Source Type: news

With ADHD, amphetamine has double the psychosis risk of methylphenidate
(Reuters Health) - Children and young adults with attention deficit-hyperactivity disorder (ADHD) who are treated with the stimulants amphetamine or methylphenidate face a small but significant risk of developing psychosis, with amphetamine products twice as likely to spark at problem, researchers say. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Popular Spice Rivals Stimulant for ADHD Popular Spice Rivals Stimulant for ADHD
The popular and expensive spice saffron appears to be as effective as the stimulant methylphenidate in treating symptoms in youngsters with ADHD, new research suggests.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 11, 2019 Category: Psychiatry Tags: Psychiatry News Source Type: news

Adhansia XR (Methylphenidate Hydrochloride Extended-release Capsules) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD
STAMFORD, Conn.--(BUSINESS WIRE) March 01, 2019 --Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR (methylphenidate hydrochloride) extended-release capsules... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 1, 2019 Category: Drugs & Pharmacology Source Type: news

Ritalin drives greater connection between brain areas key to memory, attention
(University of Wisconsin-Madison) Louis Populin and collaborators at the University of Wisconsin-Madison collaborators published a study this week in the Journal of Neuroscience describing increased connections between key parts of the brains of monkeys who have taken methylphenidate (Ritalin). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2018 Category: International Medicine & Public Health Source Type: news

Possible Tie to First-Line ADHD Drug and Psychotic Symptoms Possible Tie to First-Line ADHD Drug and Psychotic Symptoms
Noting the quality of the data may be questionable, researchers are warning clinicians about the possibility that methylphenidate may carry a risk for hallucinations and other psychotic symptoms in kids.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 30, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms
(Exeley Inc.) One of the most popular ADHD drugs may cause hallucinations and other psychotic symptoms. Research published in the SJCAPP says that possible adverse symptoms may affect 1.1 percent -- 2.5 percent of ADHD patients treated with methylphenidate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 22, 2018 Category: International Medicine & Public Health Source Type: news

Jornay PM (Methylphenidate Hydrochloride Extended-release Capsules ) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 17, 2018 Category: Drugs & Pharmacology Source Type: news

Methylphenidate Good First - Choice Pediatric ADHD Drug
For adults, amphetamines are reasonable first choice to treat attention - deficit hyperactivity disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 17, 2018 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Neurology, Nursing, Pediatrics, Pharmacy, Psychiatry, Journal, Source Type: news

Methylphenidate Good First-Choice Pediatric ADHD Drug
THURSDAY, Aug. 16, 2018 -- Methylphenidate should be considered as a first choice for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents, while amphetamines should be considered as a first choice in adults,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears First ADHD Bedtime Medication FDA Clears First ADHD Bedtime Medication
Jornay PM is a novel formulation of methylphenidate taken in the evening instead of first thing in the morning to provide early-morning control of attention-deficit/hyperactivity disorder (ADHD) symptoms.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Methylphenidate Best First-Line Drug Choice for ADHD in Kids Methylphenidate Best First-Line Drug Choice for ADHD in Kids
Methylphenidate appears to be the best first-line drug choice for attention- deficit/hyperactivity disorder (ADHD) in children and adolescents, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
GEORGE TOWN, Cayman Islands--(BUSINESS WIRE)August 09, 2018 --Ironshore Pharmaceuticals& Development, Inc. ( “Ironshore”) a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 10, 2018 Category: Drugs & Pharmacology Source Type: news

Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
The researchers compared seven ADHD drugs -- amphetamines (including lisdexamfetamine), atomoxetine, bupropion, clonidine, guanfacine, methylphenidate and modafinil -- and a placebo over 12 weeks of treatment. (Source: WebMD Health)
Source: WebMD Health - August 8, 2018 Category: Consumer Health News Source Type: news

Which Drugs Work Best for ADHD? Large Study Zeroes in on Two
WEDNESDAY, Aug. 8, 2018 -- Researchers have identified what they describe as the safest, most effective short-term drug treatments for attention deficit/hyperactivity disorder (ADHD). It's methylphenidate for kids and amphetamines for adults,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2018 Category: General Medicine Source Type: news

Ritalin-type drugs best to treat ADHD in children, shows study
Methylphenidate drugs safest and most effective while adults do better on amphetaminesRitalin and other drugs of the same class are the most effective and safest medications to prescribe for children with attention deficit hyperactivity disorder (ADHD), according to a major scientific review.The review of ADHD drugs shows that they work, and work well, in spite of concerns among the public and some doctors that children in the UK are being overmedicated. Ofsted ’s chief inspector, Amanda Spielman, has likened the drugs to a “chemical cosh” and claimed they were being overprescribed, disguising bad behavio...
Source: Guardian Unlimited Science - August 8, 2018 Category: Science Authors: Sarah Boseley Health editor Tags: Attention deficit hyperactivity disorder Mental health UK news Source Type: news

Methylphenidate best drug for hyperactive kids in short-term
But consider non-drug options first, concludes pooled analysis of data from 133 trials Related items fromOnMedica Monthly testing with isotretinoin might be unnecessary CBT helps children to kick obsessions Lorazepam no better than diazepam for child seizures Broader definition of ADHD raises risk of needless treatment One in 10 children in phase I cancer trials respond to drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 8, 2018 Category: UK Health Source Type: news

Meds not the only answer for ADHD | Letters
There need to be national multi-agency collaborative pathways for the holistic assessment of children with attention difficultiesWe, as chartered psychologists (BPS), are delighted that the inadequate provision for children with mental health difficulties in the UK was highlighted (Shocking failures on children with ADHD, 4 August). We agree with the findings that there are considerable local differences in practice in this field. We note with concern the reported rise in prescriptions for stimulant drugs such as Ritalin (methylphenidate) between 2010 and 2015. We should not fall into the trap of believing that diagnosis a...
Source: Guardian Unlimited Science - August 6, 2018 Category: Science Authors: Letters Tags: Attention deficit hyperactivity disorder Society Health Mental health NHS Conservatives Politics Psychology Science Source Type: news

UB research suggests how stimulant treatments for ADHD work
(University at Buffalo) Stimulant medications are an effective treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). In the classroom, parents and teachers say that medications like methylphenidate (MPH) can reduce symptoms and improve behavior.Although stimulants have been in use for decades to treat ADHD in school-aged children, just how they work hasn't been clear. But the results of a new study in The Journal of Child Psychology and Psychiatry is filling in critical gaps about the role of improved cognitive functions. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 27, 2018 Category: International Medicine & Public Health Source Type: news